Searchable abstracts of presentations at key conferences in endocrinology

ea0022p618 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood

Reimondo Giuseppe , Palmas Enrico , Vannelli Silvia , Bellone Jaele , Bellone Simonetta , Matarazzo Patrizia , Gasco Valentina , Borraccino Alberto , Migliaretti Giuseppe , Cavallo Franco , Ravaglia Aldo , Angeli Alberto , Aimaretti Gianluca , Terzolo Massimo

The potential side effects of the rhGH therapy have been evaluated only during treatment and the accessible databases have been developed as a post-marketing surveillance only by the Companies distributing rhGH. Aim of the present study was to evaluate health consequences (metabolic diseases and/or malignancies) in adults previously treated with rhGH during childhood. We recruited 284 patients (median age at diagnosis 12 years, range 3–17) who underwent rhGH treatment bet...

ea0016p352 | Growth and development | ECE2008

Evaluation of insulin sensitivity in growth hormone (GH) deficient children before and at the end of rhGH therapy

Savastio Silvia , Bellone Simonetta , Bellone Jaele , Zanetta Fiorella , Di Dio Giuseppina , Giacoma Sara , Petri Antonella , Prodam Flavia , Corneli Ginevra , Bona Gianni , Aimaretti Gianluca

Introduction: Therapy with recombinant GH (rhGH) allows GH-deficient children (GHD) to reach an adequate adult stature. Previous studies have reported a significant rise in serum insulin levels during GH therapy. It has been demonstrated that insulin resistance is a risk factor for the development of DMT2, atherosclerosis, dyslipidemia and hypertension.Subjects and methods: Aim of our study was to evaluate changes in insulin sensitivity in a group of GHD...